en Pediatric Hematology & Oncology Pediatric Hematology & Oncology پژوهشي Original Article <div style="text-align: justify;"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:2;"><span style="color:black"><b>Background:</b> Osteoporosis poses a significant clinical challenge for patients with hemophilia (PWH), primarily due to repeated intra-articular bleeding and joint inflammation. The objective of this study was to assess the impact of a combination of calcium-vitamin D and alendronate tablets on reducing the frequency of hemarthrosis in PWH in Lorestan province.</span><br> <span style="color:black"><b>Methods:</b> This non-randomized controlled trial involved a total of 118 PWH, out of which 55 patients with severe hemophilia A and B. Each patient underwent two assessments including the frequency and duration of bleeding episodes, and improvement in chronic joint pain, before and after receiving a combination of calcium-vitamin D, alendronate, tranexamic acid, and capsaicin ointment. Variables were measured at six-month intervals (at the beginning and end of the study). The statistical software used was SPSS version 21.</span><br> <span style="color:black"><b>Results:</b> The average age of the patients was 33.99 &plusmn; 10.67 years. The average number of target joints was 4.18 &plusmn; 0.88. A significant correlation was observed between the number of bleeding episodes before and after medication intake (p <0.0001). Similarly, a correlation was found between pre- and post-medication atrophy around the target joint in PWH (p <0.0001). However, no association was detected between joint ankylosis before and after drug administration (p = 0.5). Importantly, there was an improvement in chronic pain post-medication (p <0.0001).</span></span></span></span></div> <div style="text-align: justify;"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:2;"><b>Conclusion:</b> The findings suggest that the combination of calcium-vitamin D and low-dose intermittent alendronate can improve hemophilia joint condition.</span></span></span></div> Hemophilia, Alendronate, Hemarthrosis, Bisphosphonates, Palliative therapy 102 110 http://ijbc.ir/browse.php?a_code=A-10-190-26&slc_lang=en&sid=1 Babak Abdolkarimi b.abdolkarimi@yahoo.com 100319475328460010963 100319475328460010963 No Lorestan University of Medical Sciences, Khorramabad, Iran Javad Rostami drfrostami@gmail.com 100319475328460010964 100319475328460010964 No Lorestan University of Medical Sciences, Khorramabad, Iran Fatemeh Varehzardi varehzardi.fateme@gmail.com 100319475328460010965 100319475328460010965 No Lorestan University of Medical Sciences, Khorramabad, Iran Shadi Tabibian 100319475328460010966 100319475328460010966 Yes Iranian Comprehensive Hemophilia Care Center, Tehran, Iran Niki Panahi nikipanahi64@gmail.com 100319475328460010967 100319475328460010967 No Health service management, Science and Research branch, Islamic Azad University,Tehran, Iran